Announcement PDF Capital Raising Presentation July 2025 ampliatx.com | @ampliatx IMPORTANT INFORMATION This presentation (Presentation) has been prepared by Amplia Therapeutics Limited ACN 165 160 841 (the Company or Amplia) and is dated Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to 23 July 2025. This Presentation has been prepared in relation to a proposed capital raising comprising a placement of new ordinary fully paid change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward- shares in Amplia (New Shares) to sophisticated and professional investors (Placement or Offer). looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. This Summary Information: This Presentation contains summary information about Amplia and its activities as at the date of this Presentation. The Presentation contains such statements, which are subject to risk factors associated with an investment in Amplia. The Company believes that these information in this Presentation is of a general nature and does not purport to be complete or comprise all information which a shareholder or statements are reasonable, but they may be affected by a range of variables which could cause actual results or trends to differ materially. Forward- potential investor may require in order to determine whether to deal in Amplia shares or that would be required in a prospectus or product looking statements involve known and unknown risks, uncertainties and assumptions and other important factors that could cause actual results, disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). It should be read in conjunction with performance or achievements of Amplia to be materially different from future results, performances or achievements expressed or implied by such Amplia’s other periodic and continuous disclosure announcements lodged with the Australian Securities Exchange, which are available at statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this Presentation. www.asx.com.au. Market and industry data: This Presentation contains data relating to the industries, segments and markets in which the Company operates (Industry Restrictions: Any securities offered in connection with this Presentation have not been, and will not be, registered under the U.S. Securities Act Data). Unless otherwise stated, this information has been prepared by the Company using both publicly available data and its own internally generated of 1933, as amended (US Securities Act) or the securities laws of any state or other jurisdiction of the United States, and may not be offered or data. The Company’s internally generated data is based on estimates and assumptions that the directors and management of the Company believe are sold in the United States except in transactions exempt from, or not subject to, registration under the US Securities Act and applicable US state reasonable. In addition to the Industry Data, the Presentation contains third party market data, estimates and projections. There is no assurance regarding securities laws. This Presentation may not be distributed in the United States, or any other jurisdiction, except in accordance with the legal the accuracy of such information and the third party information, and the Industry Data, has not been independently verified by the Company. requirements applicable in such jurisdiction. The distribution of this Presentation outside Australia may be restricted by law, and persons into Financial Information: All financial information disclosed in this Presentation is presented in Australian dollars unless otherwise noted and is based on whose possession this Presentation comes should observe any such restrictions. Any failure to comply with such restrictions may violate financial information disclosed to ASX. Any discrepancies between totals and sums of components in tables and figures contained in this Presentation are applicable securities laws. due to rounding. Not financial product advice: This Presentation does not, and does not purport to, contain all information necessary to make an investment Disclaimer: No representation or warranty, express or implied, is made as to the fairness or correctness of the information, opinions and conclusions decision, is not intended as investment or financial advice (nor tax, accounting or legal advice) and must not be relied upon as such. This contained in this Presentation. To the maximum extent permitted by law Bell Potter Securities Limited (Bell Potter) and Amplia and their respective Presentation does not take into account the investment objectives, financial situation or needs of any particular investor. Investors are officers, directors, employees, agents and advisers: (1) disclaim all responsibility and liability (including, without limitation, any liability arising from fault, encouraged to seek independent professional advice when deciding if an investment in the Company is appropriate. The Company is not licensed to provide financial product advice in respect of its own securities. This Presentation is not a prospectus, product disclosure statement Presentations are tools that can negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise be used as lectures, speeches arising in connection with this Presentation; (2) disclaim any obligation or undertaking to release any update or revision to the information in this or other offering document under Australian law (or any other law). It is not, and does not constitute, an invitation or offer of securities for Presentation to reflect any change in expectations or assumptions; and (3) do not make any representation or warranty, express or implied, as to the subscription, purchase or sale in any jurisdiction. accuracy, reliability, completeness of the information in this Presentation or that this Presentation contains all material information about Amplia or that a Investment risk and past performance: An investment in Amplia shares is subject to known and unknown risks, some of which are beyond the prospective investor or purchaser may require in evaluating a possible investment in Amplia or acquisition of shares, or the likelihood of fulfilment of any control of the Company and its directors. The Company does not guarantee any particular rate of return or the performance of Amplia. Past forward-looking statement. Bell Potter and its advisers, affiliates, related bodies corporate, directors, officers, employees and agents (BP Parties) make no performance is not, and should not be relied on as being, indicative of future performance. Investors should have regard to the ‘Risks’ section of recommendations as to whether you should participate in the Offer nor do they make any representations or warranties to you concerning the Offer, and this Presentation. you represent, warrant and agree that you have not relied on any statements made by the BP Parties in relation to the Offer and you expressly disclaim Future performance and forward-looking statements: This Presentation contains certain references to forecasts, estimates, assumptions and any fiduciary duty with any of them. other forward-looking statements and statements regarding the intent, belief or current expectations of Amplia. The words “likely”, “expect”, “aim”, “should”, “could”, “may”, “anticipate”, “predict”, “believe”, “plan” and other similar expressions are intended to identify forward-looking statements. 2 EXECUTIVE SUMMARY Developing a pipeline of small molecule inhibitors of FAK – a validated cancer target Lead compound Narmafotinib is the best-in-class Focal Adhesion Kinase (FAK) inhibitor in development Promising clinical safety and tolerability positions Narmafotinib as the preferred agent to enhance activity of drugs for treatment of pancreatic cancer and other solid tumours Ongoing Phase 1b/2a ACCENT trial is evaluating Narmafotinib in combination with the chemotherapies gemcitabine and Abraxane® in patients with advanced pancreatic cancer Compelling pre-clinical data in ovarian cancer, idiopathic pulmonary fibrosis (IPF) and other solid tumours Orphan Drug and Fast Track Designations granted by US FDA – eligible for accelerated approval and Priority Review Voucher • • • • • Ongoing Phase 2a ACCENT trial in pancreatic cancer has achieved superiority over chemotherapy alone • • • • • Positive interim data released in May 2025 showed that Narmafotonib is well tolerated and promising efficacy materially exceeding the current standard of care Pathological complete response and complete response announced in June 2025 - extremely rare in advanced pancreatic cancer where the disease has metastasised Key milestone already achieved with 17 confirmed partial responses recorded, demonstrating that the combination of Narmafotinib and chemotherapy is superior to chemotherapy alone Trial is fully recruited with top-line data (PFS) expected in late July/early August 2025 Further mature data is expected in 1H 2026 Partnership Ready • • Amplia’s partnering interest from global pharmaceutical companies has materially increased following recent interim data and patient updates in the ACCENT clinical trial Management are in ongoing discussions with potential partners around regional licensing agreements Other opportunities • • • Amplicity Phase 2 trial currently recruiting under approved FDA IND - Narmafotinib in combination with FOLFIRINOX (standard-of-care therapy for advanced pancreatic cancer in US) Examining opportunities to combine Narmafotinib with kRAS inhibitors via a US investigator-initiated trial (IIT) Ovarian cancer combination trial with standard-of-care intended to commence in 1H26 - promising preclinical data and enthusiastic support from key opinion leaders in US Strong period of expected upcoming news flow • • • • • • • • ACCENT top-line data (July/August 2025) Amplicity first patient dosed (Q3 2025) ACCENT request FDA type C meeting to discuss Phase 2b/3 pivotal trial design (Q3 2025) ACCENT mature data (1H2026) kRAS and Ovarian clinical trials commence (1H 2026) ACCENT ongoing patient updates, approximately 20 patients remain on trial ACCENT commence potential pivotal Phase 2b/3 trial (2H 2026) Potential updates on licensing/partnering discussions Capital raising of approximately $27.5 million • • • Undertaking a capital raising of $27.5 million via a two-tranche placement of $25.0m and a $2.5m share purchase plan The Amplia directors will subscribe for $235,000 worth of shares (in total) under the placement, subject to shareholder approval Following the capital raising, the company will be funded into 2027 36 EXPERIENCED BOARD + MANAGEMENT Combined >120 years of drug development experience bringing 4 FDA approved drugs to market SENIOR MANAGEMENT BOARD Rhiannon Jones PhD GAICD COO Warwick Tong Robert Peach Jane Bell AM Chris Burns* MB ChB MPP GAICD Chair PhD Director LLB, LLM (Lond), FAICD Director PhD GAICD FAHMS CEO and MD Jason Lickliter MBBS FRACP CMO Tim Luscombe BCom CA GIA(Cert) CFO * Co-recipient of 2024 PM’s Prize for Innovation 4 Background on pancreatic cancer and Focal Adhesion Kinase (FAK) PANCREATIC CANCER Increasing prevalence with limited innovation or new therapies approved beyond traditional chemotherapy in recent decades Increasing Prevalence Estimated 67,440 diagnoses and 51,980 deaths in US this year* 4,641 estimated diagnoses in AU in 2024** 5 year survival Market size Difficult-to-treat: typically detected late in disease progression** Global treatment market estimated at ~US$2.65 † billon in 2024 (advanced disease) Projected to grow to † ~US$9.57 billion by 2034 * American Cancer Society: https://cancerstatisticscenter.cancer.org/ † Towards Healthcare: ** Cancer Australia: https://www.canceraustralia.gov.au/cancertypes/pancreatic-cancer/statistics https://www.towardshealthcare.com/insights/pancreaticcancer-market 6 CURRENT STANDARD OF CARE Current standard-of-care for advanced pancreatic cancer remains chemotherapy. Amplia aims to demonstrate that addition of Narmafotinib will enhance durability of response Chemotherapy Gemcitabine and nab-paclitaxel (Abraxane®) FOLFIRINOX mPFS‡ 5.5 months 7.2 months mOS‡ 8-9 months 11.1 months Comments • Regarded as better tolerated (lower adverse events), but durability less than FOLFIRINOX • Abraxane® coming off patent soon – owned by Bristol Myers Squibb • Regarded as more toxic and less well tolerated (more AE’s*) , but more durable than gem/nab-P • Off patent. New variant NALIRIFOX (Ipsen/Servier) has had poor uptake since approval ‡ mPFS = Median Progression free survival; mOS = Median Overall Survival * AE’s = Adverse Events 7 FOCAL ADHESION KINASE (FAK) FAK is a key driver of cancer progression and fibrosis, offering broad clinical potential across multiple therapeutic areas FAK is a critical protein in cancer growth and spread, and in formation of fibrotic (scar) tissue Potential applications extend beyond pancreatic cancer Capital raising to rapidly advance applications into other indications Broad clinical potential Amplia’s drugs potently and selectively block the activity of the FAK protein Cancer Fibrosis Scarring 8 FAK INHIBITION IN CANCER FAK overactivation is driving poor patient outcomes — Narmafotinib delivers an effective targeted response FAK over-expressed and over-active in many cancers Higher FAK levels correlate with worse patient outcomes Multi-action of Narmafotinib Anti-proliferative Reduces cells’ ability to proliferate and migrate Narmafotinib potently inhibits FAK and thereby reduces cancer growth Synergy with chemotherapies Enhances activity of drugs and other therapies Tumour (blue - cancer cells; green- fibroblasts; purple, grey and yellow - suppressive immune cells) • within cancer cell • in tumour microenvironment Narmafotinib blocks critical pathways supporting tumour growth Anti-fibrotic Reduces scar-tissue in TME, improving permeability to drugs Immunomodulatory Improves immune cell reactivity to tumour cells 9 LIMITED COMPETING FAK INHIBITORS Amplia is one of only 3 companies with bona fide FAK inhibitors in development VSTM.NASDAQ, Mkt Cap ~US$260m • Co-development with a second drug (avutometinib) • Targeting low-grade serous ovarian cancer (LGSOC) (~10% patients) Verastem • Accelerated FDA approval obtained in May 2025 following Phase 2 clinical trial • Confirmatory Phase 3 underway • Early data in high-grade serous ovarian cancer (HGSOC) study • High percentage patients on trial presenting with proteinuria possibly indicating off-target drug effect to kidneys Inxmed (private) • Phase 2 combination studies underway in Non-Small Cell Lung Cancer (NSCLC), Platinum- Resistant Ovarian Cancer (PROC), Colorectal Cancer (CRC) and Small Cell Lung Cancer (SCLC) Narmafotinib has an excellent selectivity profile, improved PK and excellent tolerability in patients 10 ACCENT Trial in Advanced Pancreatic Cancer PHASE 1B/2A TRIAL DESIGN Fully recruited with top-line data expected in late July/early August 2025 An open-label trial of Narmafotinib in combination with gemcitabine + nab-paclitaxel in first-line patients with advanced pancreatic cancer Trial Read-outs: Safety and Tolerabilty; Preliminary efficacy COMPLETED * Chosen dose for Phase 2a study FULLY RECRUITED 12 PHASE 1B – OCTOBER 2023 Excellent safety profile established, allowing highest dose to be selected for Phase 2A and positive efficacy signals Duration on trial Release October 2023 - Narmafotinib safe and well tolerated • All 14 patients elected to stay on drug post cycle 1 • One DLT*: uncontrolled nausea • Fatigue (Grade 3 or below) in more than 1 patient likely drug related Three dose levels examined • Taken as capsule for 4 days prior to chemotherapy • Chemotherapy given i.v. (3 doses every month) • Narmafotinib 400 mg dose (oral, once-a-day) identified as appropriate for Phase 2a study * Dose-limiting toxicity 13 PHASE 2A INTERIM DATA – MARCH 2025 Released in March 2025. Showed longer duration and median survival than chemotherapy alone and no serious adverse events Duration on Trial* High-level data (first 26 patients)* • Duration on trial average ~7 months (208 days) ⚬ Historical median duration of treatment for gemcitabine + nab-paclitaxel: 3.9 - 4.1 months • 10/26 patients on trial longer than historical mOS of 8.5-9.2 months for gem/Nab-P ⚬ Historical reference data based on MPACT and NAPOLI-3 phase 3 trials with Gem/Nab-P in mPDAC patients *Based on data available March 7, 2025; responses are investigator read; analysis may change as data matures. PR = Partial response, SD = Stable Disease, PD = Progressive Disease. 14 PHASE 2A INTERIM DATA – MARCH 2025 38% response rate compares favourably to other historical trials at 23% Collated data of ‘best response’ at Best Response (evaluable patients)* any scan indicates promising activity • 26 evaluable patients • 15 patients recorded decrease in tumor size >30% • 11 as confirmed PRs (38% response rate) ⚬ Compares favorably to historical data of 23% Color indicates best response by RECIST (target & non-target lesions): Grey = progressed; Yellow = stable disease; Green (hash) = PR (≥30% decrease from baseline); Green (solid) = confirmed PR *Based on data available in trial database on Mar 7, 2025; responses are investigator read; analysis may change as data matures. 15 PHASE 2A INTERIM DATA – MARCH 2025 Combination with gem + Abraxane leads to faster and more sustained response. If approved as a combination therapy by FDA, it has the potential for Narmafotinib combination to become far more appealing Comparison with historical gemcitabine+ Abraxane data suggests combination with Narmafotinib leads to: Response over time (all lesions)* • Faster response • Longer/sustained response Historical gemcitabine+Abraxane data § § Pancreas 2017: 46; 203 *Based on data available in trial database on Mar 7, 2025; responses are investigator read; analysis may change as data matures 16 PHASE 2A UPDATE – JUNE/JULY 2025 17 Partial Responses, including 2 Complete Responses, from 55 patients* with 20 patients remaining on trial and awaiting results Response rate sufficient to demonstrate superiority of Narmafotinib combination over gem/Nab-P alone • 17/55 patients (31%) better than 23% ORR in MPACT* study • 20 patients still on study: anticipate additional PR 2 Complete Responses recorded • 1 pathological CR - surgery followed by pathology of removed tissue • 1 confirmed CR - by CT scan, over 2 months • Both patients were existing PR patients; on trial >12 months ⚬ Confirmed CR patient remains on trial Extremely rare in metastatic advanced cancer • 1 CR from 431 patients in benchmark MPACT study† • Pathological CRs occur in ~5% of locally advanced disease ⚬ Associated with improved overall survival 17 confirmed PRs recorded (as of July 2025) • >30% reduction in tumor size sustained >2 months • No new lesions PFS to be reported end July • Sufficient patients on study for >6 months * The Phase 2a trial successfully recruited 55 patients in total, consisting of the primary 50-patient group and 5 additional participants to compensate for non-evaluable cases † New England Journal of Medicine 2013; 369: 1691 – 703 www.accenttrial.com 17 PATIENT CASE STUDY Rare pathological Complete Response in ACCENT study Patient diagnosed with stage 4 pancreatic cancer and joined ACCENT study Most patients who are diagnosed at this stage will not survive 12 months After 12 months, patient’s pancreatic tumour and liver metastases reduced in size • Surgically resectable (able to be removed by surgery) • No live cancer cells detected upon analysis Patient has recovered from surgery “I don’t know really what to say except that I’m just so happy… I was given the opportunity to have a go of it, and it’s actually worked” * Source: The Australian July 5 2025 18 TOP-LINE DATA PREVIEW Data comparison with previous gem/nab-P data from prior MPACT and NAPOLI-3 trials Full data expected to be available end of July / early August 2025 Aiming to see: • Progression free survival (PFS) and Days on trial (DOT) superior to existing chemotherapy • Continued positive safety and tolerability • Similar or improved ORR and DCR MPACT (n=431) NAPOLI (n=383) Overall survival (mo) 8.5 9.2 Progression free survival (mo) 5.5 5.6 DOT (days) 117 123 CR 0.20% 0.30% PR 23% 36% SD 27% 26% PD 20% 14.5% Not evaluable 30% 23% 23% 36% 48% 62% Confirmed Objective (Overall) response rate (ORR) (% CR, PR) Confirmed Disease control rate (DCR) (% CR, PR, or SD) 19 Potential regulatory pathway Potential for Narmafotinib to receive accelerated approval following a pivotal Phase 2b/3 clinical trial • Amplia’s Narmafotinib has potential for an accelerated path to market in in advanced pancreatic cancer following a Phase 2b/3 pivotal trial – as per Verastem, Inc • Verastem’s FAK inhibitor received FDA approval from its 184 patient Phase 2 RAMP 201 trial in recurrent Low-Grade Serous Ovarian Cancer (LGSOC) • Amplia intends to commence a Phase 2b/3 clinical trial in 2H 2026 Breakthrough and fast track designation already received (20/9/24) 2024 Request FDA meeting following release of ACCENT Phase 2a topline data. Likely to take place late 2025 / early 2026 Feedback from FDA to be received on request for pivotal Phase 2b/3 trial design 2025 Potential to commence pivotal trial in 2H26 2026 ACCENT Phase 1b/2a FDA ACCENT Type C top-line meeting* data * Type C, Type D or end-of-phase meeting Pivotal Phase 2b/3 20 ADDITIONAL OPPORTUNITIES AMPLICITY TRIAL Combining Narmafotinib with most common chemotherapy for advanced pancreatic cancer in US Phase 2 clinical study of Narmafotinib in combination with FOLFIRINOX • Strong pre-clinical evidence • FDA has cleared IND • Use modified FOLFIRINOX (better tolerability) • Protocol revision cleared by FDA (Type D meeting) • Project Optimus* compliant dose-escalation and 2 dose expansion • Part A: is expected to include 20-27 patients and is already fully funded • Part B will include 40 patients (two cohorts of 20 patients) • Part A commencing in Q3 2025 Protocol design Part A: - BOIN design; estimate 20-27 patients - Safety, PK, PD 600 mg 400 mg 200 mg Part B: - 20 patients per cohort - Safety and efficacy MTD§ from A Dose below MTD * www.fda.gov/about-fda/oncology-center-excellence/project-optimus § Maximum tolerated dose 22 kRAS Inhibitor Combinations Narmafotinib to be explored with selected kRAS inhibitor in pancreatic cancer trial kRAS inhibitors represent exciting new drug class for pancreatic, lung and colorectal cancer • Highly competitive - multiple drugs in clinical development by Pharma/Biotech worldwide • Development of resistance and product differentiation are major concerns • FAK inhibition enhances response to kRAS inhibitors in animal models (internal and published data) • Verastem’s ‘AVMAPKI FAKZYNJA CO-PACK’ is validation that FAK inhibition enhances Ras pathway inhibition in kRAS mutant cancer • IIT* concepts in discussion with pancreatic specialists • Clinical trial expected to commence in 1H 2026 * Investigator Initiated Trial FAK inhibition enhances efficacy of kRAS inhibitor Mouse model of pancreatic cancer Narmafotinib and Adagrasib (kRASi) alone and in combination 23 OVARIAN CANCER IIT’s for clinical study of Narmafotinib plus standard-of-care therapy in ovarian cancer submitted for funding and in discussion Opportunities in: • First-line therapy as a chemo-sensitiser in platinum-resistant cancer (neoadjuvant) • In recurrence and acquired resistance • In sub-type, ovarian clear cell carcinoma (~25% in Japan) Investigator initiated trial (IIT) expected to commence in 1H 2026 1 All new patients receiving chemotherapy Neoadjuvant Last platinum treatment Patients with recurrence or nonresponsive to chemotherapy 2 Refractory Sensitive 24 Outlook & catalysts PARTNERING OPPORTUNITIES Significant new partnering interest following highly prospective ACCENT clinical trial data • Amplia’s partnering interest from global pharmaceutical companies has materially increased following recent interim data and patient updates in the ACCENT clinical trial • Heightened focus in Narmafotinib as the best-in-class Focal Adhesion Kinase (FAK) inhibitor in development • Strengthened balance sheet following the capital raising will ensure the company retains flexibility to progress its clinical program and is in a position of strength when negotiating with potential license partners • Amplia’s management are in ongoing discussions with potential partners around regional licensing agreements, including: • Pharmaceutical companies with focus on orphan indications / GI cancer focus • Strategic partners with focus on drug development in precision medicine • Pharmaceutical companies with chemotherapy treatments coming off patent or seeking differentiation • Preference is to work with license partners who have specialist knowledge and capability in Amplia’s key modalities 26 UPCOMING CATALYSTS Significant pipeline of expected news flow with key catalysts imminent • Q3 2025 ✓ ACCENT top-line data including progression free survival (Late July/early August 2025) ✓ ACCENT request FDA type C meeting to discuss Phase 2b/3 pivotal trial design ✓ Amplicity first patient dosed (part A dose escalation begins) ✓ ACCENT further patient updates • Q4 2025 ✓ ACCENT further patient updates ✓ Amplicity first safety and efficacy data ✓ FDA meeting and minutes on ACCENT trial pathway Q2 Q3 ✓ Possible EU regulatory filings (Prime, Orphan) • Q4 1H 2026 ✓ ACCENT further mature data ✓ Amplicity part A dose escalation completed and further data ✓ kRAS clinical trial commences ✓ Ovarian cancer investigator initiated trial (IIT) commences • 2H 2026 ✓ Amplicity Part B commences and patient response updates ✓ ACCENT Phase 2b/3 trial commences • Potential updates on partnering / licensing agreements 27 Capital raising overview 28 CAPITAL RAISING OVERVIEW Amplia is undertaking a capital raising of $27.5m via a placement and share purchase plan Offer Structure • Amplia is undertaking a capital raising (the “Offer”) of approximately $27.5 million comprising: - an institutional placement (“Tranche 1 Placement”) to raise approximately $22.3 million utilising Amplia’s existing placement capacity under Listing Rules 7.1 and 7.1A; - an institutional placement (“Tranche 2 Placement”) to raise approximately $2.5 million subject to shareholder approval; - a placement to Amplia’s Directors to raise a total of $0.2 million, subject to shareholder approval (“Director Placement”, together the “Placement”); and - a Share Purchase Plan (“SPP”) to be made available to certain eligible shareholders to raise approximately $2.5 million, subject to shareholder approval. • Up to approximately 119.6 million new fully paid ordinary shares in Amplia (“New Shares”) to be issued under the Offer, representing approximately 30.8% of Amplia’s current shares on issue. Placement Price • New Shares issued under the Placement will be issued at a price of A$0.23 per New Share (“Placement Price”). • The Placement price represents a: - 19.3% discount to the last close price on Friday, 18 July 2025 of $0.285 - 22.8% discount to 5 trading day VWAP on Friday, 18 July 2025 of $0.298; and - 0.6% premium to 30 trading day VWAP on Friday, 18 July 2025 of $0.229; Share Purchase Plan • A Share Purchase Plan (SPP) will also be offered to eligible shareholders, with Applications up to a maximum of $100,000. • Amplia is targeting to raise approximately $2.5 million under the SPP. • New Shares will be issued under the SPP at the lower of: • The Placement price of $0.23 per New Share; or • 5.0% discount to the VWAP of the Company’s shares traded on the ASX during the 5 trading days up to the closing date of the SPP, rounded to the nearest half cent. • A transaction-specific prospectus (SPP Booklet) containing further details about the SPP, including the scale-back policy, will be made available to eligible shareholders. • Record date for determining eligibility for the SPP is 7:00pm (AEST) on Tuesday, 22 July 2025. • The Company has received binding commitments (“SPP Shortfall Commitment”) from institutional investors to subscribe for up to $2.5 million of new, fully paid ordinary shares if the SPP is not fully subscribed by eligible shareholders, subject to shareholder approval. • The Company reserves the right to accept over subscriptions under the SPP, subject to ASX Listing Rules and Corporations Act 2001 (Cth). Director Placement • Amplia’s directors have committed to subscribe for $235,000 worth of New Shares pursuant to the Director Placement, as follows (subject to shareholder approval): - Dr Robert Peach $150,000 worth of New Shares; - Dr Chris Burns - $20,000 worth of New Shares; - Dr Warwick Tong - $35,000 worth of New Shares; and - Jane Bell -$30,000 worth of New Shares Prospectus • The SPP will be undertaken pursuant to a transaction-specific prospectus. Record Date • The Record Date for the SPP is 7pm (AEST), Tuesday 22 July 2025. Ranking • All New Shares issued under the Offer will rank equally with existing Amplia shares from the date of issue. Sole Lead Manager • Bell Potter Securities Limited (“Bell Potter”) is acting as Sole Lead Manager and Bookrunner to the Offer. 29 SOURCES AND USE OF FUNDS Following the capital